Pulmonary hypertension often complicates interstitial lung disease, leading to a significantly worse prognosis. Consequently, clinicians must utilize reliable tools like ILD-PH risk stratification to monitor treatment responses effectively. While pulmonary vasodilators may improve hemodynamic parameters, they can also trigger severe hypoxemia in certain patients. Therefore, researchers investigated whether a four-stratum risk model could accurately predict outcomes following vasodilator therapy.

Clinical Impact of ILD-PH Risk Stratification

This retrospective study analyzed clinical data from 64 patients at a Japanese specialty center. Specifically, the team employed a four-stratum model based on WHO functional class, natriuretic peptide levels, and 6-minute walk distance. Initially, the cohort included patients across various risk levels, with a majority in the intermediate categories. However, after starting vasodilator therapy, nine patients showed clinical improvement, while fourteen experienced deterioration. Ultimately, the results demonstrated that post-treatment risk categories provided excellent prognostic discrimination.

Analyzing Survival and Therapy Response

Notably, the multivariate Cox analysis revealed that post-treatment risk scores are independent predictors of transplant-free survival. The study reported an adjusted hazard ratio of 3.286, which underscores the strong correlation between risk scores and survival. Furthermore, this noninvasive tool allows doctors to identify high-risk individuals who may require early lung transplant evaluation. Thus, regular assessment of ILD-PH risk stratification serves as a vital component in the management of advanced lung disease. Additionally, these findings support the use of standardized risk models to guide therapeutic adjustments in clinical practice.

Frequently Asked Questions

What parameters are used in the four-stratum risk stratification for ILD-PH?

The model primarily utilizes the World Health Organization (WHO) functional class, brain natriuretic peptide (BNP) or NT-proBNP levels, and the 6-minute walk distance (6MWD).

Why is post-treatment assessment critical in ILD-PH management?

Post-treatment assessment is crucial because it identifies how a patient responds to vasodilators. It also provides a reliable independent prediction of transplant-free survival.

Can pulmonary vasodilators be used safely in all ILD-PH patients?

While vasodilators can improve hemodynamics, they may cause severe hypoxemia in some cases. Therefore, close monitoring and systematic risk stratification are essential for patient safety.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Teramachi R et al. Early risk response to vasodilators and outcomes in interstitial lung disease associated pulmonary hypertension. Respir Investig. 2026 May 25. doi: undefined. PMID: 42184485.

Humbert M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731.

Waxman A et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med. 2021;384:325-334.